Bulletin from the extraordinary general meeting in OssDsign AB (publ)
Today, an extraordinary general meeting was held in OssDsign AB (publ) (the “Company”). Attendance at the meeting was solely possible via postal voting. Below follows a summary of the resolutions passed at the general meeting (all in accordance with the proposals presented in the notice to attend the extraordinary general meeting kept available at the Company’s website www.ossdsign.com).
The extraordinary general meeting resolved:
- on changes to the Company’s articles of association (i) regarding the limits of the share capital and (ii) regarding the limits of the number of shares;
- to approve the board of directors’ resolution on issuance of not more than 31,033,044 new shares with preferential rights for the shareholders; and
- on an authorization for the board of directors to, during the period until the next annual general meeting, with deviation from the shareholders’ preferential rights and at one or more occasions, resolve on issuance of not more than 3,875,000 new shares at a subscription price of SEK 7.75 per share.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborate with surgeons to engineer better healing by integrating biomaterials with clinical design. OssDsign is headquartered in Sweden but supplies hospitals globally with implants for use in cranial reconstructions and other orthopaedic surgery applications.
Tags: